Commentary on 'Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.' (He et al., (2020) Archives of Oral Biology, 114, 104717)

Several immune checkpoint inhibitors targeting programmed death ligand 1 (PD-L1)/programmed death 1 have successfully improved the prognosis of oesophageal squamous cell carcinoma (ESCC) with approval in certain countries. However, whether the expression of PD-L1 is associated with the degree of benefit is unclear yet and a unified standard of antibody and cut-off value of PD-L1 detection is also lacking. The current meta-analysis then aimed to explore the association between PD-L1 expression and clinicopathological features as well as prognosis in ESCC.A systematic search on PubMed, Embase, Cochrane Library and Web of Science databases was performed up to 30 March 2021. The correlation between PD-L1 expression and clinicopathological features, as well as prognosis in ESCC, was estimated with the random-effects model.A total of 5368 patients from 31 retrospective studies were enrolled. The overexpression of PD-L1 was significantly associated with lymph node metastasis (OR 1.342, 95% CI 0.995 to 1.809, p=0.050) and distant metastasis (OR 1.516, 95% CI 1.001 to 2.294, p=0.050). The pooled HR showed that PD-L1 overexpression was significantly correlated with poor overall survival (OS) of patients with ESCC (HR 1.306, 95% CI 1.108 to 1.539, p<0.010) but not disease-free survival (DFS) (HR 1.180, 95% CI 0.937 to 1.487, p=0.160). Heterogeneity decreased significantly in subgroup analyses. The overexpression of PD-L1 was associated with poor DFS at the cut-off point of ≥1% (HR 1.642, 95% CI 1.367 to 1.973, p<0.010; I2=0%) and worse OS at the cut-off point of ≥10% (HR 1.575, 95% CI 1.175 to 2.111, p<0.010; I2=0%).The overexpression of PD-L1 was correlated with lymph node and distant metastasis as well as poor survival of ESCC.

Download Full-text

Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma

Open Medicine ◽

10.1515/med-2020-0041 ◽

2020 ◽

Vol 15 (1) ◽

pp. 292-301

Author(s):

Yong-Xin Cui ◽

Xian-Shuang Su

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Death ◽

Oral Squamous Cell Carcinoma ◽

Programmed Cell Death ◽

Cell Carcinoma ◽

Squamous Cell ◽

Large Scale ◽

Meta Analysis ◽

Human Papilloma Virus Infection ◽

Clinicopathological Features

AbstractObjectiveProgrammed cell death-ligand 1 (PD-L1) expression has been shown to play important roles in various types of cancer. However, the role of PD-L1 expression has not been conclusively reported in patients with oral squamous cell carcinoma (OSCC). Accordingly, in this meta-analysis, we investigated the clinicopathological value of PD-L1 expression in patients with OSCC.MethodsGoogle Scholar, PubMed, EMBASE, and CNKI databases were searched to find relevant studies published through to September 16, 2019. The relationships between PD-L1 expression in patients with OSCC and clinicopathological features were assessed using risk ratio (RR) and 95% confidence intervals (CIs).ResultsSixteen studies including 1989 participants were included. The results indicated that high PD-L1 expression was correlated with sex (RR = 1.28, 95% CI: 1.16–1.42, P < 0.001), N stage (RR = 1.19, 95% CI: 1.06–1.33, P = 0.003), M stage (RR = 1.64, 95% CI: 1.01–2.66, P = 0.044), low differentiation (RR = 1.16, 95% CI: 1.01–1.33, P = 0.034), and human papilloma virus infection (RR = 1.38, 95% CI: 1.14–1.68, P = 0.001), but unrelated to TNM stage or T stage. There was no significant publication bias in the studies included in this analysis.ConclusionsThis meta-analysis revealed that high PD-L1 expression in patients with OSCC was correlated with clinicopathological features. Further large-scale studies are necessary to confirm our results.

Download Full-text

Dynamic contrast‑enhanced MRI as a predictor of programmed death ligand‑1 expression in patients with oral squamous cell carcinoma

Oncology Letters ◽

10.3892/ol.2021.13039 ◽

2021 ◽

Vol 22 (5) ◽

Author(s):

Nouha Tekiki ◽

Mariko Fujita ◽

Tatsuo Okui ◽

Hotaka Kawai ◽

May Oo ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Oral Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Programmed Death Ligand 1 ◽

Dynamic Contrast Enhanced Mri ◽

Dynamic Contrast Enhanced ◽

Contrast Enhanced ◽

Programmed Death ◽

Contrast Enhanced Mri

Download Full-text

Association of Programmed Death Ligand-1 Overexpression with the Grade and Stage of Oral Squamous Cell Carcinoma

Journal of College of Physicians And Surgeons Pakistan ◽

10.29271/jcpsp.2020.06.662 ◽

2020 ◽

Vol 30 (06) ◽

pp. 662-664

Keyword(s):

Squamous Cell Carcinoma ◽

Oral Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Programmed Death Ligand 1 ◽

Programmed Death

Download Full-text

The Expression of Programmed Death Ligand-1 within Stages of Oral Squamous Cell Carcinoma: Immunohistochemical Analysis

Journal of Advances in Medicine and Medical Research ◽

10.9734/jammr/2020/v32i230368 ◽

2020 ◽

pp. 59-68

Author(s):

Moomal Aslam Khan ◽

Serajuddaula Syed ◽

Noor Ul Wahab ◽

Saima Akram Butt ◽

Jabbar Ahmed Qureshi

Keyword(s):

Squamous Cell Carcinoma ◽

Oral Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Statistical Significance ◽

Clinicopathological Parameters ◽

Immunohistochemical Expression ◽

Programmed Death Ligand 1 ◽

Programmed Death ◽

Incidence And Mortality

Background: Oral squamous cell carcinoma is prevalent in South Asian countries with rising cases of its incidence and mortality. Despite advancements in treatment, survival and recurrence rates are poor. Immunotherapy is a novel therapeutic modality in immunooncology. Immune checkpoint proteins are under investigation for clinical implications amongst which Programmed Death Ligand-1 has shown valuable results in certain malignancies. Aims: To determine the immunohistochemical expression of Programmed Death Ligand-1(PD-L1) in oral squamous cell carcinoma and to find an association of Programmed Death Ligand-1 with stage and clinicopathological parameters of oral squamous cell carcinoma. Study Design: Cross-sectional study. Place and Duration of Study: Ziauddin Medical University, Karachi, 1 Year duration during 2018-2019. Methods: A total number of 140 biopsy confirmed cases of oral squamous cell carcinoma were recruited in the study. Immunohistochemical expression of Programmed Death Ligand-1 was evaluated and associated with the clinicopathological parameters of oral squamous cell carcinoma (OSCC). The data was statistically analyzed through Descriptive statistics and Chi square test by using SPSS v.20. Results: Out of 140 participants, 74% were males (n=103) and 26% were females (n=37). Programmed Death Ligand-1 positivity was observed in 62.1% of cases (n=87). The Mean age of the participants was 48.91 ± 11.7 years. The most common site of cancer involvement was buccal mucosa and majority of participants were habitual of consuming chewable products i.e. Pan, Gutka and betel nut (89; 64%). Stage III and IV tumours comprised a major portion of cases in our study. (52; 37%), (56; 40%). A statistically significant p-value was noted for the association of Programmed Death Ligand-1 with stage II and IV tumours. (P-values: 0.029, 0.001)The association of Programmed Death Ligand-1 with other variables such as age, gender, ethnicity, sites or habits was not statistically significant. Conclusion: This study concludes that the statistical significance of Programmed Death Ligand-1 expression with tumour stage is suggestive of worsening prognosis and might have detrimental effects as tumour progresses in advanced stage. Programmed Death Ligand-1 positivity in patients having oral squamous cell carcinoma could be useful in future research in the light of cancer immunotherapy which has shown success in oncology.

Download Full-text